Deutsche Biotech Innovativ (MUN:DBI) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DBI Stock Overview

Operates as a biotechnology company in Germany. More details

DBI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap (€1M)

Makes less than USD$1m in revenue (€0)

Earnings have declined by 31.7% per year over past 5 years

Deutsche Biotech Innovativ AG Competitors

bioXXmed

XTRA:T5O

€1.6m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€61.5m

Medigene

XTRA:MDG1

€23.3m

Price History & Performance

Summary of all time highs, changes and price drops for Deutsche Biotech Innovativ
Historical stock prices
Current Share Price	€1.11
52 Week High	€18.00
52 Week Low	€1.05
Beta	0
11 Month Change	1.83%
3 Month Change	0%
1 Year Change	-82.92%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-82.92%

Recent updates

Shareholder Returns

	DBI	DE Biotechs	DE Market
7D	1.8%	-1.9%	-0.2%
1Y	-82.9%	-17.2%	7.8%

Return vs Industry: DBI underperformed the German Biotechs industry which returned -13.6% over the past year.

Return vs Market: DBI underperformed the German Market which returned 13.3% over the past year.

Price Volatility

Is DBI's price volatile compared to industry and market?
DBI volatility
DBI Average Weekly Movement	1.8%
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: DBI has not had significant price volatility in the past 3 months.

Volatility Over Time: DBI's weekly volatility has decreased from 21% to 2% over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Bernd Wegener	www.dbi-ag.de

Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.

Deutsche Biotech Innovativ AG Fundamentals Summary

How do Deutsche Biotech Innovativ's earnings and revenue compare to its market cap?
DBI fundamental statistics
Market cap	€1.05m
Earnings (TTM)	-€1.09m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Is DBI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DBI income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€1.09m
Earnings	-€1.09m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.15
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did DBI perform over the long term?

See historical performance and comparison

Deutsche Biotech Innovativ MUN:DBI Stock Report